Related Experiment Video

Updated: Jun 22, 2026

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
09:37

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

Published on: July 14, 2016

Coding variant Met72Thr in the PEDF gene and risk of neovascular age-related macular degeneration and polypoidal

Hiroaki Bessho1, Naoshi Kondo, Shigeru Honda

  • 1Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Chuo-ku, Kobe, Japan.

Molecular Vision
|June 9, 2009
PubMed
Abstract

Insights

The pigment epithelium-derived factor (PEDF) Met72Thr variant is not associated with neovascular age-related macular degeneration (AMD) or polypoidal choroidal vasculopathy (PCV) in the Japanese population. This finding suggests the variant does not significantly impact the risk of developing these eye conditions.

Area of Science:

  • Ophthalmology
  • Genetics
  • Molecular Biology

Background:

  • A prior study suggested an association between the PEDF Met72Thr variant and neovascular AMD in a Taiwanese Chinese population.
  • Replication studies in a European population did not confirm this association, potentially due to differences in disease classification and patient selection, particularly regarding polypoidal choroidal vasculopathy (PCV).

Purpose of the Study:

  • To validate the association of the PEDF Met72Thr variant with neovascular age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) in a well-characterized Japanese population.

Main Methods:

  • Genotyping of the PEDF Met72Thr variant (rs1136287) was performed in 116 Japanese patients with neovascular AMD, 140 with PCV, and 189 controls using TaqMan technology.
  • Statistical analyses tested for associations under various genetic models, and population stratification was evaluated.

Main Results:

  • No statistically significant association was found between the rs1136287 variant and either neovascular AMD or PCV in the Japanese cohort across all tested genetic models (p > 0.05).
  • Population structure analyses confirmed the absence of stratification artifacts in the study population.

Conclusions:

  • The PEDF Met72Thr variant does not appear to play a significant role in the risk of developing neovascular AMD or PCV in the Japanese population.
  • These findings do not support the previously reported association, highlighting the importance of population-specific genetic studies.

More Related Videos

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System07:04

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Published on: February 4, 2021

Characterization of Vascular Morphology of Neovascular Age-Related Macular Degeneration by Indocyanine Green Angiography05:14

Characterization of Vascular Morphology of Neovascular Age-Related Macular Degeneration by Indocyanine Green Angiography

Published on: August 11, 2023

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Comparing Copy Number Variations and SNPs02:26

Comparing Copy Number Variations and SNPs

Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...